A Rare Case of Acquired Factor V Inhibitor, During Treatment with Dabigatran for Chronic Atrial Fibrillation, Successfully Treated with Bypassing Agents

Overview

Journal Clin Case Rep

Date 2021 Feb 18

PMID 33598214

Citations 2

Authors

Gaetano Giuffrida

Uros Markovic

Daniela Nicolosi

Valeria Calafiore

Affiliations

Soon will be listed here.

Abstract

Acquired factor V inhibitor represents a rare condition, described only in case reports. The use of activated bypassing agents in bleeding control could be of aid and improve the survival in symptomatic patients with acquired factor V inhibitor.

Citing Articles

Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement.

Cegledi A, Dolgos J, Fekete M, Gopcsa L, Varkonyi A, Vilimi B Pathol Oncol Res. 2023; 29:1611250.

PMID: 37334173 PMC: 10272408. DOI: 10.3389/pore.2023.1611250.

A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents.

Giuffrida G, Markovic U, Nicolosi D, Calafiore V Clin Case Rep. 2021; 9(2):623-628.

PMID: 33598214 PMC: 7869404. DOI: 10.1002/ccr3.3586.

References

Lip G . The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Int J Clin Pract. 2018; 73(2):e13285. DOI: 10.1111/ijcp.13285. View

Boersma L, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B . Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017; 14(9):1302-1308. DOI: 10.1016/j.hrthm.2017.05.038. View

Ortel T, Moore K, Quinn-Allen M, Okamura T, Sinclair A, Lazarchick J . Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood. 1998; 91(11):4188-96. View

Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, DAmbrosio G, Maglia G . Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol. 2013; 111(5):705-11. DOI: 10.1016/j.amjcard.2012.11.026. View

Giuffrida G, Markovic U, Nicolosi D, Calafiore V . A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents. Clin Case Rep. 2021; 9(2):623-628. PMC: 7869404. DOI: 10.1002/ccr3.3586. View

Cadamuro J, Skocic M, Meisl B, Raggam R, Felder T, Pruller F . A diagnostic algorithm for the detection of inhibitors against coagulation Factor V. Clin Chem Lab Med. 2015; 54(7):e203-6. DOI: 10.1515/cclm-2015-1005. View

Sekiguchi Y, Yoshikawa H, Shimada A, Imai H, Wakabayashi M, Sugimoto K . Acquired factor v inhibitor developing after treatment with dabigatran etexilate methanesulfonate: a case report and review of the literature. Indian J Hematol Blood Transfus. 2014; 30(Suppl 1):275-9. PMC: 4192195. DOI: 10.1007/s12288-014-0358-4. View

Franchini M, Lippi G . Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis. 2010; 31(4):449-57. DOI: 10.1007/s11239-010-0529-6. View

Glikson M, Wolff R, Hindricks G, Mandrola J, Camm A, Lip G . EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2019; 15(13):1133-1180. DOI: 10.4244/EIJY19M08_01. View

10.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

11.

Reddy V, Doshi S, Kar S, Gibson D, Price M, Huber K . 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017; 70(24):2964-2975. DOI: 10.1016/j.jacc.2017.10.021. View

12.

Favaloro E, Posen J, Ramakrishna R, Soltani S, McRae S, Just S . Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis. 2004; 15(8):637-47. DOI: 10.1097/00001721-200412000-00003. View

13.

Ang A, Kuperan P, Ng C, Ng H . Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost. 2009; 101(5):852-9. View

14.

Streiff M, Ness P . Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002; 42(1):18-26. DOI: 10.1046/j.1537-2995.2002.00011.x. View

15.

Olson N, Ornstein D . Factor V Inhibitors: A Diagnostic and Therapeutic Challenge. Arch Pathol Lab Med. 2017; 141(12):1728-1731. DOI: 10.5858/arpa.2016-0445-RS. View